IL123721A - תולדות אימידאזול בעלות אפיניות לקולטני אלפא 2, שיטות עבור הכנתן ותכשירי רוקחות המכילות אותן - Google Patents
תולדות אימידאזול בעלות אפיניות לקולטני אלפא 2, שיטות עבור הכנתן ותכשירי רוקחות המכילות אותןInfo
- Publication number
- IL123721A IL123721A IL12372196A IL12372196A IL123721A IL 123721 A IL123721 A IL 123721A IL 12372196 A IL12372196 A IL 12372196A IL 12372196 A IL12372196 A IL 12372196A IL 123721 A IL123721 A IL 123721A
- Authority
- IL
- Israel
- Prior art keywords
- hydrogen
- alkyl
- derivative
- hydroxy
- derivative according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Resins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9520150.5A GB9520150D0 (en) | 1995-10-03 | 1995-10-03 | New imidazole derivatives |
| PCT/FI1996/000518 WO1997012874A1 (en) | 1995-10-03 | 1996-10-02 | Imidazole derivatives having affinity for alpha2 receptors activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL123721A0 IL123721A0 (en) | 1998-10-30 |
| IL123721A true IL123721A (he) | 2004-07-25 |
Family
ID=10781676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12372196A IL123721A (he) | 1995-10-03 | 1996-10-02 | תולדות אימידאזול בעלות אפיניות לקולטני אלפא 2, שיטות עבור הכנתן ותכשירי רוקחות המכילות אותן |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6313311B1 (he) |
| EP (1) | EP0888309B1 (he) |
| JP (1) | JP4129891B2 (he) |
| KR (1) | KR19990064013A (he) |
| CN (1) | CN1068592C (he) |
| AT (1) | ATE234819T1 (he) |
| AU (1) | AU708002B2 (he) |
| BG (1) | BG63916B1 (he) |
| CA (1) | CA2231535C (he) |
| CZ (1) | CZ291576B6 (he) |
| DE (1) | DE69626862T2 (he) |
| DK (1) | DK0888309T3 (he) |
| EE (1) | EE04436B1 (he) |
| ES (1) | ES2195013T3 (he) |
| GB (1) | GB9520150D0 (he) |
| HU (1) | HU224197B1 (he) |
| IL (1) | IL123721A (he) |
| LT (1) | LT4460B (he) |
| LV (1) | LV12108B (he) |
| NO (1) | NO311024B1 (he) |
| NZ (1) | NZ319169A (he) |
| PL (1) | PL189110B1 (he) |
| PT (1) | PT888309E (he) |
| RO (1) | RO120409B1 (he) |
| RU (1) | RU2188194C2 (he) |
| SI (1) | SI9620111B (he) |
| SK (1) | SK283542B6 (he) |
| UA (1) | UA49847C2 (he) |
| WO (1) | WO1997012874A1 (he) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA981080B (en) * | 1997-02-11 | 1998-08-12 | Warner Lambert Co | Bicyclic inhibitors of protein farnesyl transferase |
| US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| AU2002254265B2 (en) * | 1997-12-04 | 2008-05-15 | Allergan, Inc. | Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors |
| BR9813381A (pt) * | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| DE69923698T2 (de) * | 1998-09-28 | 2006-01-12 | Orion Corp. | Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung |
| TWI283669B (en) * | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
| AU5537800A (en) * | 1999-06-25 | 2001-01-31 | Orion Corporation | Method of admistering an imidazole derivative to obtain analgesia |
| ATE312606T1 (de) * | 1999-10-29 | 2005-12-15 | Orion Corp | Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock |
| FI20000073A0 (fi) * | 2000-01-14 | 2000-01-14 | Orion Yhtymae Oy | Uusia imidatsolijohdannaisia |
| US6388090B2 (en) | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
| JP2003532712A (ja) | 2000-05-08 | 2003-11-05 | オリオン コーポレーション | α２アドレナリン作用活性を有する新規な多環式インダニルイミダゾール |
| TW200930291A (en) * | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
| FR2839719B1 (fr) * | 2002-05-16 | 2004-08-06 | Pf Medicament | Nouveaux composes imidazoliques, leur procede de preparation et leur utilisation a titre de medicaments |
| FI20022159A0 (fi) | 2002-12-05 | 2002-12-05 | Orion Corp | Uusia farmaseuttisia yhdisteitä |
| FI116292B (fi) * | 2003-01-08 | 2005-10-31 | Juvantia Pharma Ltd Oy | Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita |
| DE102004035322A1 (de) * | 2004-07-21 | 2006-02-16 | Universität des Saarlandes | Selektive Hemmstoffe humaner Corticoidsynthasen |
| WO2007024944A1 (en) | 2005-08-25 | 2007-03-01 | Schering Corporation | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
| US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| ES2348997T3 (es) | 2005-08-25 | 2010-12-21 | Schering Corporation | Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c. |
| JP2009524618A (ja) * | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置における２−イミダゾールの使用 |
| AU2007312390B2 (en) | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
| AU2007316257A1 (en) | 2006-11-02 | 2008-05-08 | F. Hoffmann-La Roche Ag | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
| WO2008058867A2 (en) | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
| KR101189348B1 (ko) | 2006-12-13 | 2012-10-09 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(ｔａａｒ)에 대한 리간드로서의 신규한 2-이미다졸 |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| ES2510546T3 (es) | 2007-02-02 | 2014-10-21 | F. Hoffmann-La Roche Ag | Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC |
| BRPI0807961A2 (pt) | 2007-02-13 | 2017-05-16 | Pharmacopeia Llc | agonista de alfa2c adrenorreceptor funcionalmente seletivos. |
| CA2678069A1 (en) | 2007-02-13 | 2008-08-21 | Schering Corporation | Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists |
| EP2398776A1 (en) * | 2007-02-13 | 2011-12-28 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| CN101687812A (zh) | 2007-07-02 | 2010-03-31 | 弗·哈夫曼-拉罗切有限公司 | 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物 |
| KR101150628B1 (ko) | 2007-07-03 | 2012-05-31 | 에프. 호프만-라 로슈 아게 | 4-이미다졸린 및 항우울제로서 이의 용도 |
| CN101765587A (zh) | 2007-07-27 | 2010-06-30 | 弗·哈夫曼-拉罗切有限公司 | 作为taar配体的2-氮杂环丁烷甲胺类和2-吡咯烷甲胺类 |
| KR101167773B1 (ko) | 2007-08-03 | 2012-07-24 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ１ 리간드로서의 피리딘카복스아마이드 및 벤즈아마이드 유도체 |
| WO2009105504A2 (en) | 2008-02-21 | 2009-08-27 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| TW201026691A (en) | 2008-10-07 | 2010-07-16 | Schering Corp | Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators |
| EP3305281A1 (en) | 2009-05-15 | 2018-04-11 | Recro Pharma, Inc. | Sublingual dexmedetomidine compositions and methods of use thereof |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US8673950B2 (en) | 2010-11-02 | 2014-03-18 | Hoffmann-Laroche Inc. | Dihydrooxazol-2-amine derivatives |
| US8802673B2 (en) | 2011-03-24 | 2014-08-12 | Hoffmann-La Roche Inc | Heterocyclic amine derivatives |
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| CA2858721C (en) | 2011-12-11 | 2021-03-16 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
| KR101631003B1 (ko) | 2012-01-12 | 2016-06-15 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체 |
| EA026062B1 (ru) | 2012-09-14 | 2017-02-28 | Ф. Хоффманн-Ля Рош Аг | Производные пиразолкарбоксамида в качестве модуляторов рецепторов следовых аминов (taar) для применения при лечении различных расстройств, таких как депрессия, диабет и болезнь паркинсона |
| HK1206714A1 (en) * | 2012-09-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Triazole carboxamide derivatives |
| WO2015165085A1 (en) | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| CN106470994B (zh) | 2014-08-27 | 2019-09-24 | 豪夫迈·罗氏有限公司 | 用于治疗cns疾病的取代的吡嗪并[2,1-a]异喹啉衍生物 |
| KR101894681B1 (ko) | 2014-08-27 | 2018-09-04 | 에프. 호프만-라 로슈 아게 | Taar 리간드로서의 치환된 아제티딘 유도체 |
| MY195528A (en) | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
| CN116496261B (zh) * | 2023-03-09 | 2025-06-27 | 中国人民解放军军事科学院军事医学研究院 | 4-(1h)-咪唑类衍生物及其医药用途 |
| CN118684628B (zh) * | 2024-05-20 | 2025-06-17 | 中国人民解放军军事科学院军事医学研究院 | 取代二氢茚基咪唑类化合物及其制备方法和用途 |
| CN119424420B (zh) * | 2024-11-15 | 2025-11-21 | 中国人民解放军军事科学院军事医学研究院 | 取代二氢茚基咪唑类化合物的抗肿瘤用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3636002A (en) * | 1969-12-15 | 1972-01-18 | Janssen Pharmaceutica Nv | 1-(2-halobenzyloxy-1-indanyl)-imidazoles |
| ES8503669A1 (es) * | 1982-07-05 | 1985-03-01 | Erba Farmitalia | Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos. |
| US4634705A (en) * | 1984-06-06 | 1987-01-06 | Abbott Laboratories | Adrenergic amidines |
| US4659730A (en) * | 1984-06-18 | 1987-04-21 | Eli Lilly And Company | Aromatase inhibiting imidazole derivatives |
| GB2167408B (en) * | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| FI81092C (fi) * | 1986-05-15 | 1990-09-10 | Farmos Oy | Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat. |
| US4878940A (en) * | 1987-04-02 | 1989-11-07 | Janssen Pharmaceutica N.V. | Herbicidal 1,5-substituted 1H-imidazoles |
| IL91542A0 (en) * | 1988-10-06 | 1990-04-29 | Erba Carlo Spa | N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them |
| GB2225782A (en) * | 1988-12-09 | 1990-06-13 | Farmos Group Limited | Imidazole derivatives useful for treatment of diabetes |
| GB9127050D0 (en) * | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
| GB9425211D0 (en) * | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| US6388090B2 (en) * | 2000-01-14 | 2002-05-14 | Orion Corporation | Imidazole derivatives |
-
1995
- 1995-10-03 GB GBGB9520150.5A patent/GB9520150D0/en active Pending
-
1996
- 1996-10-02 IL IL12372196A patent/IL123721A/he not_active IP Right Cessation
- 1996-10-02 NZ NZ319169A patent/NZ319169A/xx not_active IP Right Cessation
- 1996-10-02 EP EP96932609A patent/EP0888309B1/en not_active Expired - Lifetime
- 1996-10-02 ES ES96932609T patent/ES2195013T3/es not_active Expired - Lifetime
- 1996-10-02 JP JP51399497A patent/JP4129891B2/ja not_active Expired - Lifetime
- 1996-10-02 AU AU71327/96A patent/AU708002B2/en not_active Expired
- 1996-10-02 PL PL96328167A patent/PL189110B1/pl unknown
- 1996-10-02 US US09/051,151 patent/US6313311B1/en not_active Expired - Lifetime
- 1996-10-02 EE EE9800101A patent/EE04436B1/xx unknown
- 1996-10-02 SI SI9620111A patent/SI9620111B/sl unknown
- 1996-10-02 PT PT96932609T patent/PT888309E/pt unknown
- 1996-10-02 CZ CZ19981018A patent/CZ291576B6/cs not_active IP Right Cessation
- 1996-10-02 UA UA98031588A patent/UA49847C2/uk unknown
- 1996-10-02 RU RU98108027/04A patent/RU2188194C2/ru active
- 1996-10-02 SK SK439-98A patent/SK283542B6/sk not_active IP Right Cessation
- 1996-10-02 DE DE69626862T patent/DE69626862T2/de not_active Expired - Lifetime
- 1996-10-02 HU HU9802927A patent/HU224197B1/hu active IP Right Grant
- 1996-10-02 CN CN96197438A patent/CN1068592C/zh not_active Expired - Lifetime
- 1996-10-02 CA CA002231535A patent/CA2231535C/en not_active Expired - Lifetime
- 1996-10-02 RO RO98-00825A patent/RO120409B1/ro unknown
- 1996-10-02 WO PCT/FI1996/000518 patent/WO1997012874A1/en not_active Ceased
- 1996-10-02 AT AT96932609T patent/ATE234819T1/de active
- 1996-10-02 DK DK96932609T patent/DK0888309T3/da active
- 1996-10-02 KR KR1019980702490A patent/KR19990064013A/ko not_active Ceased
-
1998
- 1998-03-12 BG BG102324A patent/BG63916B1/bg unknown
- 1998-03-31 LV LVP-98-61A patent/LV12108B/en unknown
- 1998-04-02 NO NO19981496A patent/NO311024B1/no not_active IP Right Cessation
- 1998-04-22 LT LT98-057A patent/LT4460B/lt not_active IP Right Cessation
-
2001
- 2001-07-16 US US09/904,836 patent/US6479530B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0888309B1 (en) | Imidazole derivatives having affinity for alpha2 receptors activity | |
| US6972299B2 (en) | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | |
| FI91857B (fi) | Menetelmä terapeuttisesti aktiivisten alfa-heterosykleillä substituoitujen tolunitriilien valmistamiseksi | |
| JP2009524616A (ja) | Ｃｎｓ疾患のための４−イミダゾール誘導体の使用 | |
| CA2190865A1 (fr) | Derives d'imidazole (ant)agonistes du recepteur h3 de l'histamine | |
| FI83310C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1- piperazinyl/propyl/-2,4-dihydro-3h-1,2,4-triazol-3-onderivat. | |
| EP0824098A1 (en) | 4-hydroxy-piperidine derivatives | |
| FI81092B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat. | |
| MXPA02006872A (es) | Nuevos derivados de imidazol. | |
| HK1014951B (en) | Imidazole derivatives having affinity for alpha2 receptors activity | |
| JPH08509502A (ja) | イミダゾールリポキシゲナーゼ阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |